BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

BNP Paribas Financial Markets boosted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 59.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 88,029 shares of the biotechnology company’s stock after acquiring an additional 32,841 shares during the period. BNP Paribas Financial Markets owned approximately 0.07% of Arrowhead Pharmaceuticals worth $1,655,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Ameriprise Financial Inc. lifted its holdings in Arrowhead Pharmaceuticals by 2.6% during the fourth quarter. Ameriprise Financial Inc. now owns 224,988 shares of the biotechnology company’s stock worth $4,230,000 after acquiring an additional 5,732 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its holdings in Arrowhead Pharmaceuticals by 63.1% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 632,214 shares of the biotechnology company’s stock worth $11,886,000 after acquiring an additional 244,527 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Arrowhead Pharmaceuticals by 11.4% in the fourth quarter. Northern Trust Corp now owns 1,484,419 shares of the biotechnology company’s stock valued at $27,907,000 after purchasing an additional 151,654 shares in the last quarter. Tudor Investment Corp ET AL lifted its holdings in shares of Arrowhead Pharmaceuticals by 6.6% in the fourth quarter. Tudor Investment Corp ET AL now owns 66,573 shares of the biotechnology company’s stock valued at $1,252,000 after purchasing an additional 4,149 shares in the last quarter. Finally, Aquatic Capital Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 80.9% in the fourth quarter. Aquatic Capital Management LLC now owns 169,394 shares of the biotechnology company’s stock valued at $3,185,000 after purchasing an additional 75,776 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on ARWR shares. Citigroup cut their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. StockNews.com upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 14th. Finally, B. Riley restated a “buy” rating and issued a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $42.13.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $15.71 on Monday. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The stock’s 50-day simple moving average is $13.30 and its 200 day simple moving average is $17.78. The company has a market cap of $2.17 billion, a P/E ratio of -3.04 and a beta of 0.89. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to analyst estimates of $116.27 million. During the same period in the prior year, the firm posted ($1.02) EPS. As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 50,800 shares of the business’s stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $11.49, for a total transaction of $583,692.00. Following the transaction, the chief executive officer now owns 3,921,255 shares of the company’s stock, valued at $45,055,219.95. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 275,880 shares of company stock valued at $4,034,037. 4.30% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.